Washington: The US Federal Food and Drug Administration has approved a new drug for the treatment of Alzheimer’s disease.
According to media reports, in clinical trials, the drug Kisunla has shown the ability to slow the rate of thinking and memory decline in patients in the early stages of Alzheimer’s disease.
Anne White, president of Lilly Neuroscience, said that kisunla has shown strong therapeutic results in patients with early stages of Alzheimer’s disease who require immediate treatment.
Ann added that the drug has the greatest benefit when patients are treated early in the early stages of their disease, while we work hard with others to improve early diagnosis. are doing Every year more and more people are at risk of this disease and we are committed to making life better for them.
Dr. Howard Filt, co-founder and chief science officer of the Alzheimer’s Drug Discovery Foundation, said the FDA’s approval marks an important advance in improving the quality of care for people with Alzheimer’s disease. I will eventually add new treatments. This development is a hope for the Alzheimer’s community.
Leave feedback about this